SCHEMBL7763178

SCHEMBL7763178

COC(=O)c1ccc(NC(=O)C(NC(=O)C(CCc2ccccc2)CC(=O)O)C(C)(C)C)cc1

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 20/20 0.74
MMP3 P08254 8/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7762285 0.95 MMP2 (0.82) MMP2MMP3
SCHEMBL7758470 0.91 MMP2 (0.75) MMP2MMP3
SCHEMBL7758488 0.88 MMP2 (0.56) MMP2MMP3
SCHEMBL7761449 0.86 MMP2 (0.83) MMP2MMP3
SCHEMBL7758581 0.83 MMP3 (0.61) MMP2MMP3
SCHEMBL7762295 0.82 MMP2 (0.62) MMP2MMP3
SCHEMBL8773903 0.81 MMP2 (0.72) MMP2MMP3
SCHEMBL7762157 0.78 MMP2 (0.58) MMP2MMP3
SCHEMBL9289897 0.76 MMP3 (0.58) MMP2MMP3
SCHEMBL7763773 0.76 MMP3 (0.62) MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP claimed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO claimed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed